Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.80 |
| ▸ | ITGAV | P06756 | 20/20 | 0.80 |
| ▸ | ITGB6 | P18564 | 15/20 | 0.80 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.80 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.72 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.72 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2833667 | 0.96 | ITGB3 (0.73) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL2837439 | 0.89 | ITGB3 (0.90) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL5848894 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL5848125 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL5847961 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL2833671 | 0.88 | ITGB3 (0.65) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| Hydrochloric Acid SCHEMBL5848208 | 0.88 | ITGB3 (0.98) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| Hydrochloric Acid SCHEMBL5848813 | 0.88 | ITGB3 (0.98) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL5859391 | 0.88 | ITGB3 (0.74) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL2833556 | 0.88 | ITGB3 (0.79) | ITGB3ITGAVITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019246317-A9 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | PROGENITY, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ITGB3 10/4885ITGAV 11/4885ITGB6 6/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | ITGB3 989/4885ITGAV 1195/4885ITGB6 1427/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | ITGB3 1048/4885ITGAV 351/4885ITGB6 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.